| Mussa Banisadre, MD | |
|
1325 Melrose Ave, Suite A, Modesto, CA 95350-5508 | |
| (209) 524-7000 | |
| (209) 527-5601 |
| Full Name | Mussa Banisadre |
|---|---|
| Gender | Male |
| Speciality | Hematology |
| Experience | 51 Years |
| Location | 1325 Melrose Ave, Modesto, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043264690 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | A38740 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Doctors Medical Center | Modesto, CA | Hospital |
| Oak Valley Hospital District | Oakdale, CA | Hospital |
| Doctors Hospital Of Manteca | Manteca, CA | Hospital |
| Adventist Health Sonora | Sonora, CA | Hospital |
| Emanuel Medical Center | Turlock, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stockton Hematology Oncology Medical Group Inc | 1456369800 | 8 |
News Archive
Sentinelle Medical Inc., a leading manufacturer of breast MRI coils and 4D advanced visualization software, extends its line of award winning breast coils at this year's Radiological Society of North America (RSNA) annual meeting in Chicago, Nov. 30 - Dec. 5, 2009 (Booth 5800, Hall A).
Consumer Watchdog today condemned Blue Cross's transfer of $2.8 billion to its parent company since 2007, including approximately $719.5 million in 2009 alone, as a way of hiding its true financial condition from regulators scrutinizing steep rate hikes. Consumer Watchdog said Insurance Commissioner Steve Poizner should seize on the transfers to invalidate recent premium hikes and should make Blue Cross documents available for public scrutiny.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 862,500 shares of its common stock and warrants to purchase an additional 431,250 shares (15% of the shares and warrants sold in this offering), at a public offering price of $4.00 per share and $0.001 per warrant, respectively, in connection with its previously announced underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase up to an aggregate of 2,875,000 shares of common stock, bringing the total gross proceeds from the offering to approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.
Unlike the three most common forms of breast cancer, triple negative breast cancer has no currently approved targeted therapies for treatment. That was one of the reasons it was chosen as a disease area of focus for the Indiana University Precision Health Grand Challenge initiative, aimed to research and develop better treatments, cures or preventions, as quickly as possible.
› Verified 2 days ago
| Entity Name | Stockton Hematology Oncology Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922175074 PECOS PAC ID: 1456369800 Enrollment ID: O20060328000211 |
News Archive
Sentinelle Medical Inc., a leading manufacturer of breast MRI coils and 4D advanced visualization software, extends its line of award winning breast coils at this year's Radiological Society of North America (RSNA) annual meeting in Chicago, Nov. 30 - Dec. 5, 2009 (Booth 5800, Hall A).
Consumer Watchdog today condemned Blue Cross's transfer of $2.8 billion to its parent company since 2007, including approximately $719.5 million in 2009 alone, as a way of hiding its true financial condition from regulators scrutinizing steep rate hikes. Consumer Watchdog said Insurance Commissioner Steve Poizner should seize on the transfers to invalidate recent premium hikes and should make Blue Cross documents available for public scrutiny.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 862,500 shares of its common stock and warrants to purchase an additional 431,250 shares (15% of the shares and warrants sold in this offering), at a public offering price of $4.00 per share and $0.001 per warrant, respectively, in connection with its previously announced underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase up to an aggregate of 2,875,000 shares of common stock, bringing the total gross proceeds from the offering to approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.
Unlike the three most common forms of breast cancer, triple negative breast cancer has no currently approved targeted therapies for treatment. That was one of the reasons it was chosen as a disease area of focus for the Indiana University Precision Health Grand Challenge initiative, aimed to research and develop better treatments, cures or preventions, as quickly as possible.
› Verified 2 days ago
| Entity Name | California Cancer Care Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033163688 PECOS PAC ID: 1153402698 Enrollment ID: O20080122000760 |
News Archive
Sentinelle Medical Inc., a leading manufacturer of breast MRI coils and 4D advanced visualization software, extends its line of award winning breast coils at this year's Radiological Society of North America (RSNA) annual meeting in Chicago, Nov. 30 - Dec. 5, 2009 (Booth 5800, Hall A).
Consumer Watchdog today condemned Blue Cross's transfer of $2.8 billion to its parent company since 2007, including approximately $719.5 million in 2009 alone, as a way of hiding its true financial condition from regulators scrutinizing steep rate hikes. Consumer Watchdog said Insurance Commissioner Steve Poizner should seize on the transfers to invalidate recent premium hikes and should make Blue Cross documents available for public scrutiny.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 862,500 shares of its common stock and warrants to purchase an additional 431,250 shares (15% of the shares and warrants sold in this offering), at a public offering price of $4.00 per share and $0.001 per warrant, respectively, in connection with its previously announced underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase up to an aggregate of 2,875,000 shares of common stock, bringing the total gross proceeds from the offering to approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.
Unlike the three most common forms of breast cancer, triple negative breast cancer has no currently approved targeted therapies for treatment. That was one of the reasons it was chosen as a disease area of focus for the Indiana University Precision Health Grand Challenge initiative, aimed to research and develop better treatments, cures or preventions, as quickly as possible.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mussa Banisadre, MD 1325 Melrose Ave, Suite A, Modesto, CA 95350-5508 Ph: (209) 524-7000 | Mussa Banisadre, MD 1325 Melrose Ave, Suite A, Modesto, CA 95350-5508 Ph: (209) 524-7000 |
News Archive
Sentinelle Medical Inc., a leading manufacturer of breast MRI coils and 4D advanced visualization software, extends its line of award winning breast coils at this year's Radiological Society of North America (RSNA) annual meeting in Chicago, Nov. 30 - Dec. 5, 2009 (Booth 5800, Hall A).
Consumer Watchdog today condemned Blue Cross's transfer of $2.8 billion to its parent company since 2007, including approximately $719.5 million in 2009 alone, as a way of hiding its true financial condition from regulators scrutinizing steep rate hikes. Consumer Watchdog said Insurance Commissioner Steve Poizner should seize on the transfers to invalidate recent premium hikes and should make Blue Cross documents available for public scrutiny.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 862,500 shares of its common stock and warrants to purchase an additional 431,250 shares (15% of the shares and warrants sold in this offering), at a public offering price of $4.00 per share and $0.001 per warrant, respectively, in connection with its previously announced underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase up to an aggregate of 2,875,000 shares of common stock, bringing the total gross proceeds from the offering to approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.
Unlike the three most common forms of breast cancer, triple negative breast cancer has no currently approved targeted therapies for treatment. That was one of the reasons it was chosen as a disease area of focus for the Indiana University Precision Health Grand Challenge initiative, aimed to research and develop better treatments, cures or preventions, as quickly as possible.
› Verified 2 days ago
Brian E. Dolnick, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4601 Dale Rd, Modesto, CA 95356 Phone: 209-557-1000 | |
Dr. Joshua Mckee Anderson, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4601 Dale Rd, Modesto, CA 95356 Phone: 209-735-7200 | |
Sulman Razzaq, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1409 E Briggsmore Ave, Modesto, CA 95355 Phone: 209-550-4750 | |
Alvin K Eng, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1540 Florida Ave, # 100, Modesto, CA 95350 Phone: 209-577-5557 Fax: 209-577-8125 | |
Esra Olgun, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 600 Coffee Rd, Modesto, CA 95355 Phone: 209-521-6097 | |
Ronak Chandrakant Shah, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 600 Coffee Rd, Modesto, CA 95355 Phone: 209-521-6097 | |
Dr. Paul Golden, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1330 Nelson Ave, Suite C, Modesto, CA 95350 Phone: 209-576-1547 Fax: 209-576-2736 |